Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

Paolo Caimi, MD, discusses the rationale behind evaluating LMY-920, a novel BAFF CAR T-cell therapy, in relapsed/refractory non-Hodgkin lymphoma.

Dr Caimi on Early Data for LMY-920 in R/R B-Cell NHL

David H. Aggen, MD, PhD, details the evolving landscape of treating patients with urothelial carcinoma.

Navigating a “Sea Change” in Frontline Urothelial Carcinoma Treatment

Jennifer Scalici, MD, discusses data for IMNN-001plus chemotherapy in advanced ovarian cancer.

Dr Scalici on Data for IMNN-001 Plus SOC Chemotherapy in Advanced Ovarian Cancer

Steven H. Lin, MD, PhD, discusses the safety of NKTR-255 in enhancing immune recovery post-chemoradiation in locally advanced NSCLC.

Dr Lin on the Safety of NKTR-255 in Enhancing Immune Recovery Post-Chemoradiation in Locally Advanced NSCLC

News

OncClub

All Oncology News

Media

Insights

MedNews Week

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

CME/CE

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Webinars

Partners

Publications

Resources

Interactive Tools

Biomarker Consortium

Subscribe

 in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Articles

The FDA has granted accelerated approval to zanidatamab for pretreated, advanced HER2-positive biliary tract cancer.

FDA Approves Zanidatamab for Previously Treated, Unresectable or Metastatic HER2+ Biliary Tract Cancer

Caroline Seymour is your initial point of contact for the 

™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com​ 

 
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource 

. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Osimertinib has been recommended for approval in patients with locally advanced, unresectable, EGFR-mutant NSCLC after chemoradiation.

Osimertinib Approaches EU Approval in Locally Advanced EGFR+ NSCLC After Chemoradiation

An NDA for lisaftoclax in relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma has been accepted for review. 

Lisaftoclax NDA Accepted for Review in China for Relapsed/Refractory CLL/SLL

Ryan Scott joined MJH Life Sciences in 2021. In addition to writing and editing timely news and article coverage, she manages 

 social media accounts; check us out @onclive across platforms such as LinkedIn, Facebook, X, and Instagram! She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: 

David R. Oveisi, MD, discusses how the expanded indications for ide-cel and cilta-cel are affecting treatment decision-making in multiple myeloma.

Expanded Indications for CAR T-Cell Therapies Shepard in New Era of Myeloma Care

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

Specialty

Continuing Education

26th Annual International Lung Cancer Congress®

42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®

PER LIVER CANCER TUMOR BOARD: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable HCC Impact Multidisciplinary Patient Management Today, and Tomorrow?

Balazs Halmos, MD, MS; Kristen K. Ciombor, MD, MSCI; Joyce O’Shaughnessy, MD; Daniel P. Petrylak, MD 

Community Practice Connections™: Clinical Updates from Chicago – A Focus on What Community Centers Need to Know to Move Their Solid Tumors' Practices Forward

Maurie Markman, MD; Rachel N. Grisham, MD; Bhavana Pothuri, MD

  Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?

Howard I. Scher, MD; Scott T. Tagawa, MD, MS, FACP; Mary-Ellen Taplin, MD

Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?

Andre H. Goy, MD; Sandra M. Swain, MD, FACP, FASCO Associate Dean for Research; Carolina Bernabe Ramirez, MD; Jonathan E. Rosenberg, MD; David H. Vesole, MD, PhD, FACP Director, Myeloma Program; Isabel Preeshagul, DO, MBS  
 

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

Vivek Subbiah, MD; Brian A. Van Tine, MD, PhD

Tumor Agnostic Trials and the Reshaping of Precision Medicine in Oncology: A Focus on TSC1/2 Mutations

Community Practice Connections™: Optimize the Diagnosis and Treatment of HER2-Positive Colorectal Cancer

Community Oncology Connections™: Controversies and Conversations About HER2-Expressing Breast Cancer… Advances in Management from HER2-Low to Positive Disease

Annual Hematology Meeting: Preceding the 66th ASH Annual Meeting and Exposition

David Planchard, MD, PhD; Martin F. Dietrich, MD, PhD

How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities

Benjamin P. Levy, MD; Komal Jhaveri, MD, FACP; Joshua K. Sabari, MD

Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!

Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer

Joseph R. Mikhael, MD, MEd, FRCPC, FACP; Ajai Chari, MD; Caitlin Costello, MD; Krina Patel, MD, MSc

Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat

George M. Rodgers III, MD, PhD; Patricia A. Ford, MD; Sidharth Anand, MD, MBA

Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?

Andrew Kuykendall, MD; Naveen Pemmaraju, MD; Barbara Mora, MD; Gabriela Hobbs, MD

Show Me the Data: How Do We Navigate the Latest Evidence on Novel Therapies, Combinations, and Clinical Trials Across MPN Care in the Context of Current Treatment Algorithms?

Towards Personalized Treatment Approaches in Soft Tissue Sarcomas

22nd Annual Winter Lung Cancer Conference®

Brendon M. Stiles, MD; Jamie E. Chaft, MD; Balazs Halmos, MD, MS

 Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…

Tanios Bekaii-Saab, MD, FACP; Aiwu Ruth He, MD, PhD; Eugene J. Koay, MD

The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape

42nd Annual Miami Breast Cancer Conference®

Heather McArthur, MD, MPH; William J. Gradishar, MD, FASCO, FACP; Jennifer Keating Litton, MD, MHCM; Debu Tripathy, MD

 The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…

Nicole Lamanna, MD; William Wierda, MD, PhD; Jennifer A. Woyach, MD

Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions

Tanios Bekaii-Saab, MD, FACP; Richard S. Finn, MD; Aiwu Ruth He, MD, PhD; Eugene J. Koay, MD

18th Annual New York GU Cancers Congress™

Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma

Andre H. Goy, MD; Marco L. Davila, MD, PhD; Ajay K. Nooka, MD, MPH, FACP

Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy

Kevin Kalinsky, MD, MS; Komal Jhaveri, MD, FACP; Reshma L. Mahtani, DO; Kelly McCann, MD, PhD

Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care

E. Gabriela Chiorean, MD, FASCO; John L. Marshall, MD; Diana L. Hanna, MD; Syma Iqbal, MD; Heloisa P. Soares, MD, PhD Associate Professor 

  Community Practice Connections™: 9th Annual School of Gastrointestinal Oncology®

Exploring the Benefits and Risks of AI in Oncology

BURST CME™: Illuminating the Crossroads of Precision Medicine and Targeted Treatment Options in Metastatic CRC

Karen M. Winkfield, MD, PhD; Narjust Florez, MD, FASCO; Gilberto de Lima Lopes Junior, MD, MBA, FASCO; Coral Olazagasti, MD; Vonetta M. Williams, MD, PhD

 Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Peter Robert Galle, MD, PhD; Amit Singal, MD, MS; Linda L. Wong, MD; Ghassan Abou-Alfa, MD, MBA; Han Chong Toh, MD 

Community Practice Connections™: 14th Asia-Pacific Primary Liver Cancer Expert Meeting

Matt Lunning DO, FACP; Kami Maddocks, MD; Grzegorz S. Nowakowski, MD, FASCO; Sarah C. Rutherford, MD

Contextualizing Advances in Relapse Refractory DLBCL: Navigating Biomarkers, Emerging Data, and Adverse Event Management to Transform Patient Care

Burst CME™: Tackling Adverse Events With Targeted Therapies for Diffuse B-Cell Lymphoma

Matt Lunning, DO, FACP; Sarah C. Rutherford, MD

 Biomarkers in Diffuse Large B-Cell Lymphoma: Empowering Treatment Decisions to Improve Outcomes

Matt Lunning, DO, FACP; Grzegorz S. Nowakowski, MD., FASCO

 Treating Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Current Options and Emerging Approaches

Corey Cutler, MD, MPH, FRCP(C); Carrie L. Kitko, MD

BURST Expert Illustrations and Commentaries™: Exploring the Mechanistic Rationale for CSF-1R– Directed Treatment in Chronic GVHD

Asim V. Farooq, MD; Joann Kang, MD; Nita Lee, MD, MPH

Upcoming CME Events & Activities

EVENTS

ACTIVITIES

Latest Conference Coverage